Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Finckh

Showing results (161-170 of 225) with videos related to

Pageof 23
Sort By:
BMJ Open|July 15, 2021
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritisBenoit Thomas P Gilbert, Céline Lamacchia, Denis Mongin, et al.
Rheumatology (Oxford, England)|May 17, 2022
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyAndrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, et al.
Annals of the Rheumatic Diseases|June 8, 2010
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyWilliam G Dixon, Loreto Carmona, Axel Finckh, et al.
RMD Open|November 2, 2019
Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?Denis Mongin, Kim Lauper, Carl Turesson, et al.
Clinical Rheumatology|December 15, 2016
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
Rheumatology (Oxford, England)|January 27, 2021
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritisCeline Lamacchia, Delphine S Courvoisier, Matthias Jarlborg, et al.
Frontiers in Immunology|November 29, 2023
The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel diseaseMarcio Luis Acencio, Marek Ostaszewski, Alexander Mazein, et al.
Rheumatology (Oxford, England)|June 19, 2019
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionKim Lauper, Denis Mongin, Deshire Alpizar-Rodriguez, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAdrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, et al.
Pageof 23

Showing results (161-170 of 225) with videos related to

Sort By:
Pageof 23
BMJ Open|July 15, 2021
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritisBenoit Thomas P Gilbert, Céline Lamacchia, Denis Mongin, et al.
Rheumatology (Oxford, England)|May 17, 2022
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapyAndrea Amstad, Eleftherios Papagiannoulis, Almut Scherer, et al.
Annals of the Rheumatic Diseases|June 8, 2010
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatologyWilliam G Dixon, Loreto Carmona, Axel Finckh, et al.
RMD Open|November 2, 2019
Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?Denis Mongin, Kim Lauper, Carl Turesson, et al.
Clinical Rheumatology|December 15, 2016
Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA)Florenzo Iannone, Delphine S Courvoisier, Jacques Eric Gottenberg, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritisAdrian Ciurea, Almut Scherer, Ulrich Weber, et al.
Rheumatology (Oxford, England)|January 27, 2021
Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritisCeline Lamacchia, Delphine S Courvoisier, Matthias Jarlborg, et al.
Frontiers in Immunology|November 29, 2023
The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel diseaseMarcio Luis Acencio, Marek Ostaszewski, Alexander Mazein, et al.
Rheumatology (Oxford, England)|June 19, 2019
Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolutionKim Lauper, Denis Mongin, Deshire Alpizar-Rodriguez, et al.
Annals of the Rheumatic Diseases|September 23, 2020
Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortAdrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, et al.
Pageof 23